The next time you’re due for a medical exam you may get a call from someone like Ana: a friendly voice that can help you prepare for your appointment and answer any pressing questions you might have.
With her calm, warm demeanor, Ana has been trained to put patients at ease — like many nurses across the U.S. But unlike them, she is also available to chat 24–7, in multiple languages, from Hindi to Haitian Creole.
01:13 How Does Tesla Bot Gen 3 Handle Real-World Tasks? 06:12 How much does the Tesla Bot Gen 3 truly cost? 10:36 How is Tesla planning to sell the Bot Gen 3? === New UPDATE! Elon Musk LEAKED Tesla Bot Gen 3 10K Mass Production & All Real-Life Tasks Testing! Recently, Elon Musk confidently announced that the Tesla Bot Optimus can navigate independently in 95% of complex environments and react in just 20 milliseconds! With a plan to produce 10,000 Tesla Optimus Gen 3 units in 2025, Tesla is leveraging its AI infrastructure, manufacturing capabilities, and real-world testing across more than 1,000 practical tasks to prepare for mass production this year.
New UPDATE! Elon Musk LEAKED Tesla Bot Gen 3 10K Mass Production & All Real-Life Tasks Testing! In today’s episode, we have compiled evidence from official announcements, technical demonstrations to validate the feasibility of this plan and pinpoint the final timeline and pricing for the 2025 production model. But before we dive into price analysis in Part 2 and exactly launching time in Part 3 of this episode, you should first understand what we expect from this Tesla humanoid robot—and more importantly, whether it’s truly worth the price. How Does Tesla Bot Gen 3 Handle Real-World Tasks?
New UPDATE! Elon Musk LEAKED Tesla Bot Gen 3 10K Mass Production & All Real-Life Tasks Testing! John Kennedy, nearly seventy, lay motionless on the floor, pain radiating from his hip and spine. His phone was just a few steps away—close, yet out of reach. Then, everything went dark. A humanoid robot detected his fall. It gently lifted him up, scanned his injuries, and instantly sent an alert to his doctor. Then came the doctor’s words, they wanted to send him to an assisted living facility.
In this episode, Peter answers the hardest questions about AI, Longevity, and our future at an event in El Salvador (Padres y Hijos).
Recorded on February 2025 Views are my own thoughts; not Financial, Medical, or Legal Advice.
Chapters.
00:00 — Navigating Confusion in Leadership and Purpose. 02:00 — The Evolution of Work and Purpose. 03:50 — AI’s Role in Information Credibility. 07:17 — Sustainability and Technology’s Impact on Nature. 09:26 — Building a Future with AI and Longevity. 11:40 — The Economics of Longevity and Accessibility. 15:15 — Reimagining Education for the Future. 19:23 — Overcoming Human Obstacles to Progress.
I send weekly emails with the latest insights and trends on today’s and tomorrow’s exponential technologies. Stay ahead of the curve, and sign up now: https://www.diamandis.com/subscribe.
Join the free, hour-long Journal of Virology Seminar Series webinars, where authors will present their recently published Journal of Virology® (JVI) articles and share the story behind their research with the wider academic community. Presentations are followed by an open forum panel discussion with all speakers and participants. JVI editors will moderate the sessions, including the discussion and live Q&A.
Join us for the second webinar in the Journal of Virology Seminar Series, where we’ll explore the New York City Virus Hunters community science initiative. Christine Marizzi, Ph.D., and Phillip Meade, Ph.D., will introduce this exciting program, which brings together community scientists, veterinarians, wildlife rehabilitators and virologists to generate actionable data in urban areas and help prepare for future pandemics.
During the seminar, the New York City Virus Hunters team will share their latest findings on avian influenza in the city’s wild bird population. Program alumni Kailani Gaynor and Sadia Choudhury will also discuss their experiences as youth researchers. Don’t miss this opportunity to connect and learn about the critical role of community science in virology.
By combining drugs/therapies with different mechanisms of action, different pathways in cancer cells can be targeted, potentially leading to improved patient outcomes. Using AI is hastening this research.
Artificial intelligence can transform medicine in a myriad of ways, including its promise to act as a trusted diagnostic aide to busy clinicians.
Over the past two years, proprietary AI models, also known as closed-source models, have excelled at solving hard-to-crack medical cases that require complex clinical reasoning. Notably, these closed-source AI models have outperformed open-source ones, so-called because their source code is publicly available and can be tweaked and modified by anyone.
“Anyone with lungs can get lung cancer.” Kelly thought it couldn’t happen to her—until it did. Having worked at Pfizer for over 25 years, she knew how an unexpected diagnosis could suddenly turn someone’s life upside down, but nothing could have prepared her for her own cancer journey.
After developing a chronic cough, Kelly was looking for answers. She had appointments with several healthcare providers and specialists who diagnosed her with everything from gastroesophageal reflux disease to long COVID. Nothing gave her relief. Kelly’s symptoms only got worse; her cough soon became debilitating, and she developed shortness of breath. After months of frustration, she decided to take matters into her own hands and called a friend who works as a pulmonologist. After hearing her symptoms, he booked Kelly for a CT scan right away. Minutes after the test was complete, she received news that turned her life upside down—she had cancer.
Despite significant advancements, millions of people across the globe face a cancer diagnosis each year. For the Pfizer Oncology team, these individuals are more than a statistic—they are parents, children, friends and colleagues.
In this Review, Ahmad et al. examine how antibiotics influence bacterial metabolism and how metabolism, in turn, affects drug efficacy and the emergence and evolution of antimicrobial resistance. They also explore the role of bacterial metabolism in clinical contexts and the potential for metabolic-based therapies to improve antibacterial treatment.
